Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Switzerland, Germany, the United States, Austria, Netherlands, the United Kingdom, France, Belgium, and internationally. The company offers pharmaceutical products for treating oncology, neuroscience, infectious, immunology, cardiovascular and metabolism, ophthalmology, and respiratory, as well as anemia, cancer, dermatology, hemophilia, inflammatory and autoimmune, neurological, and transplantation. It also offers in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and other diseases. In addition, the company supplies diagnostic instruments and reagents. The company was founded in 1896 and is headquartered in Basel, Switzerland.
Revenue of Roche Holding AG (ROG.SW)
Revenue in 2023 (TTM): $67.63 B
According to Roche Holding AG's latest financial reports the company's current revenue (TTM) is $67.63 B. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of Roche Holding AG
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $67.63 B | $49.33 B | $20.6 B | $15.75 B | $12.87 B |
| 2022 | $70.81 B | $49.73 B | $23.27 B | $18.32 B | $13.9 B |
| 2021 | $70.27 B | $48.23 B | $24.83 B | $19.47 B | $15.59 B |
| 2020 | $65.26 B | $46.96 B | $25.7 B | $20.1 B | $16 B |
| 2019 | $71.33 B | $51.88 B | $24.12 B | $18.59 B | $15.1 B |
| 2018 | $66.57 B | $48.09 B | $20.52 B | $15.83 B | $11.75 B |
| 2017 | $62.38 B | $44.6 B | $18.73 B | $13.71 B | $9.66 B |
| 2016 | $58.9 B | $42.02 B | $19.77 B | $14.55 B | $10.72 B |
| 2015 | $56.4 B | $40.46 B | $21.32 B | $13.41 B | $9.92 B |
| 2014 | $55.8 B | $41.28 B | $21.41 B | $14 B | $10.44 B |
| 2013 | $54.4 B | $40.54 B | $20.31 B | $16.42 B | $12.49 B |
| 2012 | $50.91 B | $37.29 B | $17.91 B | $13.79 B | $10.67 B |
| 2011 | $47.59 B | $34.23 B | $17.59 B | $13.3 B | $10.45 B |
| 2010 | $53.12 B | $38.25 B | $17.53 B | $12.54 B | $9.7 B |
| 2009 | $54.89 B | $38.53 B | $16.45 B | $11.45 B | $8.71 B |
| 2008 | $51.04 B | $35.76 B | $19.04 B | $15.85 B | $10.04 B |
| 2007 | $51.62 B | $36.24 B | $20.29 B | $17.12 B | $10.92 B |
| 2006 | $47.04 B | $35.16 B | $17.21 B | $14.08 B | $8.82 B |
| 2005 | $39.74 B | $29.32 B | $13.2 B | $10.03 B | $7.53 B |
| 2004 | $34.99 B | $26.96 B | $11.84 B | $10.61 B | $7.43 B |
| 2003 | $34.93 B | $25.63 B | $7.95 B | $5.46 B | $3.43 B |
| 2002 | $33.26 B | $23.83 B | $3.19 B | $-3,573,966,259 | $-4,504,943,067 |
| 2001 | $32.63 B | $23.3 B | $5.37 B | $5.33 B | $4.14 B |
| 2000 | $32.08 B | $21.83 B | $30.85 B | $10.59 B | $9.68 B |
| 1999 | $30.85 B | $20.92 B | $9.93 B | $8.45 B | $6.45 B |
| 1998 | $27.6 B | $18.75 B | $7.21 B | $6.1 B | $4.91 B |